Reckitt Benckiser
publicUKRBGLY
$14B annual revenue
Fines & Settlements
$1900M
FTC / FDA Violations6
2023lawsuitJury verdict $500M (appeal pending)$500.0M
Multi-state lawsuit against Reckitt Benckiser/Mead Johnson: premature infant NEC (necrotizing enterocolitis) linked to Enfamil cow's milk-based formula; Illinois jury awarded $500M verdict; science linking bovine formula to NEC in preemies known to Mead Johnson; failure to warn hospitals and parents
2022EU regulatory actionWHO Code violation - multiple countries
WHO Code violation investigation: Reckitt/Mead Johnson marketing of Enfamil in Southeast Asia and Africa violated International Code of Marketing of Breast-milk Substitutes; promotional materials to healthcare workers, free samples to hospitals, and misleading labels; IBFAN (International Baby Food
2021FTC actionConsent Order
FTC action against Reckitt Benckiser/Mead Johnson: misleading 'brain-building' and cognitive development claims on Enfamil infant formula; DHA/ARA content claims implied clinical developmental benefits not supported by scientific consensus; prohibited from unsubstantiated cognitive development claim
2021EU regulatory actionEU RASFF notification - unauthorized disease prevention claims
EU RASFF notification: Dettol antiseptic liquid (Reckitt) — labeling claims exceed permitted cosmetic/biocide boundaries under EU Regulation 528/2012; product marketed with disease prevention claims not permitted under EU biocide regulations; UK/EU notified
2020FDA warning letterWarning Letter Issued
Warning letter to Reckitt Benckiser: misleading disease treatment claims on Lysol products marketed as killing COVID-19; claims not authorized by FDA; advertising implied Lysol prevents SARS-CoV-2 transmission before efficacy data was available
2019lawsuitDOJ settlement $1.4B$1400.0M
DOJ investigation and $1.4B resolution against Reckitt Benckiser: fraudulent marketing of Suboxone (buprenorphine/naloxone) film strips; manipulated transition from tablets to film to extend market exclusivity; illegal payments to physicians; largest opioid treatment drug settlement
Lobbying Record$12M documented
2023$1Minfant formula regulations, healthcare policy, FDA reform
2022$1Minfant formula shortage policy, FDA oversight, WHO code
2021$1Minfant formula marketing standards, healthcare advertising, opioid settlement
2020$1MCOVID-related health regulations, infant formula supply, drug safety
2019$2Mopioid crisis legislation, infant formula regulations, healthcare policy
2018$1Mopioid policy, infant formula WHO code, drug pricing
2017$1Mopioid regulations, infant formula marketing, healthcare advertising
2016$1Minfant formula marketing, WHO code compliance, FDA enforcement
2015$1Minfant formula marketing, OTC drug regulations, import standards
FDA Recalls2 total
2022[Class I] Reckitt Benckiser/Mead Johnson Nutrition: Enfamil NeuroPro infant formula — Cronobacter sakazakii contamination risk at Zeeland, MI facility; nationwide recall; same contamination risk as Abbott Similac recall that triggered 2022 infant for
2021[Class II] Reckitt Benckiser: Mucinex DM liquid — manufacturing quality control failures; incorrect active ingredient concentration; consumer health risk; voluntary nationwide recall of multiple lot numbers